



EHA2023 abstracts

What's hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA2023 Congress, the Multiple Myeloma Hub Steering Committee have provided their recommendations of the top abstracts to look for in multiple myeloma.



This educational resource is supported through funds from pharmaceutical companies — a full list of our supporters can be found at <https://multiplemyelomahub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

Top abstracts in multiple myeloma and other plasma cell dyscrasias

<u>S100</u>	<u>First phase 3 results from CARTITUDE-4: Cilta-cel versus standard of care (PvD or DPd) in lenalidomide-refractory multiple myeloma</u>	Hermann Einsele
<u>S190</u>	<u>First results from the REDIRECTT-1 study with teclistamab (TEC) + talquetamab (TAL) simultaneously targeting BCAM and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)</u>	Maria-Victoria Mateos
<u>S192</u>	<u>Talquetamab (TAL) + daratumumab (DARA) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Updated TRIMM-2 results</u>	Nizar J Bahlis
<u>S195</u>	<u>Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KARMMA-3 analysis in high-risk subgroups</u>	Krina Patel
<u>S197</u>	<u>LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma</u>	Hans C Lee
<u>S199</u>	<u>A phase 3, open-label, randomized study evaluating the efficacy and safety of single agent belantamab mafodotin vs pomalidomide plus dexamethasone in relapsed/refractory multiple myeloma (DREAMM-3)</u>	Meletios Dimopoulos
<u>S202</u>	<u>CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma</u>	Nikhil Munshi
<u>S203</u>	<u>Quadruplet induction therapy, ASCT and MRD-modulated consolidation and treatment cessation in newly diagnosed multiple myeloma: Final analysis of the MASTER trial</u>	Luciano Costa
<u>S204</u>	<u>Safety and tolerability of CAEL-101, an anti-amyloid monoclonal antibody, combined with anti-plasma cell dyscrasia therapy in patients with light-chain amyloidosis: 18-month results of a phase 2 study</u>	Jason Valent
<u>P870</u>	<u>Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma and prior B-cell maturation antigen (BCMA)-directed therapies: A pooled analysis from MAGNETISM studies</u>	Salomon Manier





Follow us on Twitter to keep up to date with the latest from the EHA2023 Congress!

@MM_Hub

#EHA2023

multiplemyelomahub.com



Scientific Education Support